Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities.
Front Neurol
; 12: 676095, 2021.
Article
in English
| MEDLINE | ID: covidwho-1526775
ABSTRACT
Treatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) patients. There are an increasing number of new therapeutic agents for AOMS, and many will be formally studied for use also in POMS. However, there are important efficacy and safety concerns regarding the use of these therapies in children and young adults. This review will discuss the current state of the art of POMS therapy and will focus on the newer therapies (oral and infusion disease-modifying drugs) and on those still currently under investigation.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Observational study
/
Prognostic study
Language:
English
Journal:
Front Neurol
Year:
2021
Document Type:
Article
Affiliation country:
Fneur.2021.676095
Similar
MEDLINE
...
LILACS
LIS